特发性矮小症与生长激素治疗儿童脊柱侧凸
本研究通过横断面和回顾性队列研究,发现特发性矮小症儿童脊柱侧凸患病率显著高于对照组(33.1% vs 8.52%,OR 3.722,p<0.001)。纵向分析显示,生长激素治疗增加基线无脊柱侧凸患儿发生脊柱侧凸及需支具治疗的风险,但对已有脊柱侧凸者的进展、支具或手术需求无显著影响。
要点
- 特发性矮小症儿童脊柱侧凸患病率33.1%,显著高于对照组的8.52%(OR 3.722,p<0.001)。
- 基线无脊柱侧凸者接受生长激素治疗增加发生脊柱侧凸风险(p=0.015)和支具需求(p<0.001)。
- 基线已有脊柱侧凸者,生长激素治疗未增加进展、支具或手术风险。
核心结论
- 生长激素对特发性矮小症儿童脊柱侧凸的影响被认为可控,但医生应密切关注这些儿童的脊柱曲度评估。
研究设计与样本
- 横断面研究纳入2053例特发性矮小症儿童和4106例年龄、性别匹配(1:2)的无矮小症儿童,均有全脊柱X线片。
- 纵向研究从上述人群中纳入1056例特发性矮小症儿童和790例有两次以上X线片的对照,评估脊柱侧凸的发生、进展及支具和手术需求。
主要发现
- 横断面研究中,特发性矮小症儿童脊柱侧凸患病率为33.1%(681/2053),对照组为8.52%(350/4106),比值比3.722(p<0.001),多数病例为轻度。
- 纵向研究中,特发性矮小症儿童发生和进展脊柱侧凸的风险高于对照组。
- 基线无脊柱侧凸的特发性矮小症儿童中,生长激素治疗显著增加发生脊柱侧凸的风险(p=0.015)和支具需求(p<0.001)。
- 基线有脊柱侧凸的特发性矮小症儿童中,生长激素治疗未增加脊柱侧凸进展、支具需求或手术的风险。
关键数值与推荐
- 横断面研究:特发性矮小症组脊柱侧凸患病率33.1%(681/2053),对照组8.52%(350/4106),比值比3.722(p<0.001)。
- 纵向研究:基线无脊柱侧凸者中,生长激素治疗增加脊柱侧凸发生风险(p=0.015)和支具需求(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prevalence of scoliosis is not known in patients with idiopathic short stature, and the impact of treatment with recombinant human growth hormone on those with scoliosis remains controversial. We investigated the prevalence of scoliosis radiologically in children with idiopathic short stature, and the impact of treatment with growth hormone in a cross-sectional and retrospective cohort study. A total of 2,053 children with idiopathic short stature and 4,106 age- and sex-matched (1:2) children without short stature with available whole-spine radiographs were enrolled in the cross-sectional study. Among them, 1,056 with idiopathic short stature and 790 controls who had radiographs more than twice were recruited to assess the development and progression of scoliosis, and the need for bracing and surgery. In the cross-sectional study, there was an unexpectedly higher prevalence of scoliosis (33.1% (681/2,053) vs 8.52% (350/4,106)) in children with idiopathic short stature compared with controls (odds ratio 3.722; p < 0.001), although most cases were mild. In the longitudinal study, children with idiopathic short stature had a higher risk of the development and progression of scoliosis than the controls. Among children with idiopathic short stature without scoliosis at baseline, treatment with growth hormone significantly increased the risk of developing scoliosis (p = 0.015) and the need for bracing (p < 0.001). Among those with idiopathic short stature and scoliosis at baseline, treatment with growth hormone did not increase the risk of progression of the scoliosis, the need for bracing, or surgery. The impact of treatment with growth hormone on scoliosis in children with idiopathic short stature was considered controllable. However, physicians should pay close attention to the assessment of spinal curves in these children.
引用
- Hong H, Pan X, Song J, et al. Idiopathic short stature and scoliosis in children treated with growth hormone. Bone Joint J. 2023. PMID: 36924176. doi:10.1302/0301-620X.105B4.BJJ-2022-0898.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。